Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births
By Christy Santhosh
July 8 (Reuters) -Pfizer's PFE.N respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.
The vaccine Abrysvo was approved by the U.S. Food and Drug Administration last year for women in their second or third trimesters of pregnancy to prevent infections tied to RSV in babies in the first six months after birth.
However, some experts had raised concerns over a higher number of pre-term births among participants taking the Pfizer shot compared to those who received a placebo in the company's clinical trial.
Researchers from Weill Cornell Medical College in New York conducted the retrospective study in women who were 24 to 36 weeks into pregnancy, and found no significant statistical difference between the vaccinated women's pre-term birth rate of 5.9% compared with unvaccinated women's 6.7%.
Health regulators however recommended a narrower gestational window, said Annette Regan, from the University of San Francisco's School of Nursing and Health Professions, in an editorial accompanying the study.
"Despite the need for further research and surveillance, results from this study should offer initial reassurance to regulators, policymakers, health care professionals, and pregnant patients," Regan wrote in the article published in JAMA.
In most of the continental U.S., the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend the vaccine for women who are 32 to 36 weeks pregnant between September and January.
The study analyzed electronic health records of women across two New York City hospitals who gave birth between September last year to late January.
RSV leads to the hospitalization of about 58,000 to 80,000 children younger than 5 years annually.
Pfizer's vaccine is the only maternal RSV shot approved in the US. The vaccine, along with rivals by GSK GSK.L and Moderna MRNA.O, is also approved for older adults.
Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
